Utang jangka cendhak marang modal Cingulate (CING)

Cingulate Inc. (CING) is a recognized biopharmaceutical player developing advanced methods for treating ADHD. The stock price history demonstrates the dynamics of an asset currently valued at 0.25. Experts value the brand for its progressive therapeutic developments, maintaining a positive image. The company's revenues rely on the sale of precision-release drugs through insurance funds and pharmacies.

This indicator measures the proportion of liabilities maturing within one year relative to equity, allowing for an assessment of refinancing risks during a period of rising interest rates. By analyzing the current trend of short-term liabilities to equity, an investor can weigh the debt load against the high pricing power of Cingulate Inc. (CING), which is driven by the uniqueness of the CTRX platform and inelastic demand for ADHD therapy.